Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Valneva, Chikungunya
Chikungunya ‘stooping disease’ explained as UK approves first vaccine
The world’s first vaccine for mosquito-borne chikungunya virus has been approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The disease strikes around half a million people every year and climate change has increased the risk of transmission in Europe. So what is it and why do we need a vaccine?
Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults. France-based Valneva has also submitted label extension applications in the US,
MHRA grants Valneva marketing authorization for chikungunya vaccine
Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United
Valneva rises after U.K. approval of chikungunya vaccine
Shares of Valneva (NASDAQ:VALN) traded higher on Wednesday after the French biotech announced that the U.K.’s Medicines and Healthcare Products Regulatory Agency granted marketing authorization for its chikungunya vaccine.
Valneva receives authorisation for world’s first Chikungunya vaccine
Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is indicated for active immunisation for the prevention of disease caused by Chikungunya virus (CHIKV) in individuals 18 years of age and older.
Valneva jumps 19% after chikungunya vaccine wins UK approval
Shares of Valneva (VALN), a specialty vaccine company closed up over $1.00 per share or almost 19% to close the regular session at $6.67 per
UK grants approval for Valneva’s chikungunya vaccine
French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), marking the fourth regulatory approval for the world’s first vaccine against the virus.
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci
13d
Valneva Is A 'Buy' As A First-Mover In Chikungunya
Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...
Medscape
5d
EMA Expedites Adolescent Chikungunya Vaccine Recommendation
Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...
pharmaphorum
3d
CHMP backs Bavarian Nordic's chikungunya jab
Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...
GMA Network
1d
Davao City logs 5 suspected chikungunya cases
At least five suspected cases of chikungunya were recorded in Davao City in January 2025. The residents who were suspected of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Valneva
United Kingdom
Ixchiq
Medicines and Healthcare products Regulatory Agency
Feedback